Chloroquine-resistant Plasmodium Malariae in South Sumatra, Indonesia

Lancet. 2002 Jul 6;360(9326):58-60. doi: 10.1016/S0140-6736(02)09336-4.

Abstract

Oral chloroquine is the treatment of choice for uncomplicated Plasmodium malariae infections worldwide. We did a prospective 28-day in-vivo assessment of the efficacy of chloroquine for treatment of P malariae on Legundi Island in Lampung Bay, Sumatra, Indonesia. Of 28 patients, one had recurrent parasitaemia on day 28, and two had persistent parasitaemia to day 8. Whole-blood chloroquine and desethylchloroquine concentrations were at ordinarily effective levels (> or = 100 microg/L) on day 8 in both cases of persistent parasitaemia. These findings suggest that clinical resistance to chloroquine by P malariae occurs in the Indonesian archipelago of southeast Asia.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Animals
  • Antimalarials / blood
  • Antimalarials / therapeutic use*
  • Child
  • Chloroquine / blood
  • Chloroquine / therapeutic use*
  • Drug Resistance
  • Female
  • Humans
  • Indonesia / epidemiology
  • Malaria, Falciparum / blood
  • Malaria, Falciparum / drug therapy*
  • Malaria, Falciparum / epidemiology
  • Malaria, Vivax / blood
  • Malaria, Vivax / drug therapy*
  • Malaria, Vivax / epidemiology
  • Male
  • Middle Aged
  • Plasmodium falciparum / isolation & purification*
  • Plasmodium vivax / isolation & purification*
  • Polymerase Chain Reaction
  • Prevalence
  • Prospective Studies

Substances

  • Antimalarials
  • Chloroquine